The roughly 15 million clients of genetic information outfit 23andMe could also be at larger danger than they understand, suggests a brand new New York Occasions story that argues the corporate’s near-term woes may grow to be problematic for others for a really very long time if it will possibly’t proceed as a going concern.
Actually, with every passing day, the hope of founder and CEO Anne Wojcicki to take it personal once more appears extra like fantasy. The corporate, valued at $6 billion when it went public in 2021, is now valued at $150 million. It’s poised to be delisted subsequent month. Press tales aren’t serving to. (Would you purchase a equipment?)
The corporate says it stays dedicated to “observe legal guidelines that regulate the info we gather,” however all that genomic information within the incorrect arms may very well be an issue that worsens. As a Yale biomedical professor observes to the Occasions, a hacked bank card may be changed; a genome can not. In the meantime, the tech that analyzes genomes is advancing. Chances are high it’ll grow to be extra revealing, too.